BP Figure 7: AZD1656 increases liver steatosis in the Gckr^del/wt mouse.

Gckr^wt/wt and Gckr^del/wt were fed on a HFD without (open bar) or with (shaded) 3 mg/kg AZD1656 for 16 wk. A) Lowering of blood glucose by AZD1656 after 4 wk and 14 wk in Gckr^wt/wt and Gckr^del/wt mice. B) Higher plasma insulin by Gckr^del/wt genotype at 4 wk and 14 wk. C) Impaired glucose tolerance in AZD1656-treated Gckr^del/wt mice. D) Increased plasma FFA by AZD1656 treatment in Gckr^del/wt mice. E) Increased plasma cholesterol by AZD1656 treatment in Gckr^del/wt mice. F) Increased liver / body weight ratio by AZD1656 treatment in Gckr^del/wt mice. G) Increased liver triglyceride by AZD1656 treatment in Gckr^del/wt mice. H) Higher hepatocyte steatosis, microvesicular steatosis and fibrosis scores by AZD1656 treatment in Gckr^del/wt mice. I) Representative haematoxylin and eosin (H&E) and Sirius red fast green (SRFG) images for histopathology scores, scale bar 200µm. J) Liver mRNA levels (RT-qPCR) for the genes indicated expressed as a ratio to RplpO showing increased expression of Fgf21, Cidea and Cidec by AZD1656 treatment in the Gckr^del/wt mice: n= 10 and 11 for Gckr^wt/wt (-/+) and n= 6 and 10 for Gckr^del/wt (-/+) *P < 0.05 effect of AZD1656; #P < 0.05 effect of genotype.